Therapeutics Stocks Shine in Q2: Amgen Leads Charge

The therapeutics stock sector had a strong Q2, with revenues beating analysts' consensus estimates by 8% and share prices up 26.4% on average since the latest earnings results.

Amgen (NASDAQ:AMGN), founded in 1980, reported revenues of $10.05 billion, up 9.5% year-over-year, exceeding analysts' expectations by 6.9%. The company's six key growth drivers grew 26% year-over-year, generating nearly 70% of second-quarter product sales.

Biogen (NASDAQ:BIIB), founded in 1978, reported revenues of $2.74 billion, up 3.4% year-over-year, outperforming analysts' expectations by 12.1%. The company had an incredible quarter with a beat of analysts' EPS estimates and a solid beat of analysts' full-year EPS guidance estimates.

On the other hand, Myriad Genetics (NASDAQ:MYGN) reported revenues of $190.7 million, down 10.5% year-over-year, falling short of analysts' expectations by 8.2%. The company delivered the weakest performance against analyst estimates and weakest full-year guidance update of the whole group.